Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institut...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Maselli DJ [verfasserIn] Rogers L [verfasserIn] Peters JI [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade

Übergeordnetes Werk:	In: Therapeutics and Clinical Risk Management - Dove Medical Press, 2009, (2018), Seite 2059-2068
Übergeordnetes Werk:	year:2018 ; pages:2059-2068

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ075226855

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ075226855
003	DE-627
005	20230309132941.0
007	cr uuu---uuuuu
008	230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ075226855
035			\|a (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RM1-950
100	0		\|a Maselli DJ \|e verfasserin \|4 aut
245	1	0	\|a Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody
650		4	\|a MEDI-563
650		4	\|a benralizumab
650		4	\|a anti-IL-5
650		4	\|a IL-5 blockage
650		4	\|a IL-5 receptor blockade
653		0	\|a Therapeutics. Pharmacology
700	0		\|a Rogers L \|e verfasserin \|4 aut
700	0		\|a Peters JI \|e verfasserin \|4 aut
773	0	8	\|i In \|t Therapeutics and Clinical Risk Management \|d Dove Medical Press, 2009 \|g (2018), Seite 2059-2068 \|w (DE-627)481905820 \|w (DE-600)2180573-8 \|x 1178203X \|7 nnns
773	1	8	\|g year:2018 \|g pages:2059-2068
856	4	0	\|u https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-203X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2018 \|h 2059-2068

Indexfelder

author_variant	m d md r l rl p j pj
matchkey_str	article:1178203X:2018----::erlzmbndotetetosvresnpiiatmeautooeaebtosmrecdprmnvst
hierarchy_sort_str	2018
callnumber-subject-code	RM
publishDate	2018
allfields	(DE-627)DOAJ075226855 (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b DE-627 ger DE-627 rakwb eng RM1-950 Maselli DJ verfasserin aut Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade Therapeutics. Pharmacology Rogers L verfasserin aut Peters JI verfasserin aut In Therapeutics and Clinical Risk Management Dove Medical Press, 2009 (2018), Seite 2059-2068 (DE-627)481905820 (DE-600)2180573-8 1178203X nnns year:2018 pages:2059-2068 https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b kostenfrei https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM kostenfrei https://doaj.org/toc/1178-203X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 2059-2068
spelling	(DE-627)DOAJ075226855 (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b DE-627 ger DE-627 rakwb eng RM1-950 Maselli DJ verfasserin aut Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade Therapeutics. Pharmacology Rogers L verfasserin aut Peters JI verfasserin aut In Therapeutics and Clinical Risk Management Dove Medical Press, 2009 (2018), Seite 2059-2068 (DE-627)481905820 (DE-600)2180573-8 1178203X nnns year:2018 pages:2059-2068 https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b kostenfrei https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM kostenfrei https://doaj.org/toc/1178-203X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 2059-2068
allfields_unstemmed	(DE-627)DOAJ075226855 (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b DE-627 ger DE-627 rakwb eng RM1-950 Maselli DJ verfasserin aut Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade Therapeutics. Pharmacology Rogers L verfasserin aut Peters JI verfasserin aut In Therapeutics and Clinical Risk Management Dove Medical Press, 2009 (2018), Seite 2059-2068 (DE-627)481905820 (DE-600)2180573-8 1178203X nnns year:2018 pages:2059-2068 https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b kostenfrei https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM kostenfrei https://doaj.org/toc/1178-203X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 2059-2068
allfieldsGer	(DE-627)DOAJ075226855 (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b DE-627 ger DE-627 rakwb eng RM1-950 Maselli DJ verfasserin aut Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade Therapeutics. Pharmacology Rogers L verfasserin aut Peters JI verfasserin aut In Therapeutics and Clinical Risk Management Dove Medical Press, 2009 (2018), Seite 2059-2068 (DE-627)481905820 (DE-600)2180573-8 1178203X nnns year:2018 pages:2059-2068 https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b kostenfrei https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM kostenfrei https://doaj.org/toc/1178-203X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 2059-2068
allfieldsSound	(DE-627)DOAJ075226855 (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b DE-627 ger DE-627 rakwb eng RM1-950 Maselli DJ verfasserin aut Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade Therapeutics. Pharmacology Rogers L verfasserin aut Peters JI verfasserin aut In Therapeutics and Clinical Risk Management Dove Medical Press, 2009 (2018), Seite 2059-2068 (DE-627)481905820 (DE-600)2180573-8 1178203X nnns year:2018 pages:2059-2068 https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b kostenfrei https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM kostenfrei https://doaj.org/toc/1178-203X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 2059-2068
language	English
source	In Therapeutics and Clinical Risk Management (2018), Seite 2059-2068 year:2018 pages:2059-2068
sourceStr	In Therapeutics and Clinical Risk Management (2018), Seite 2059-2068 year:2018 pages:2059-2068
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	Therapeutics and Clinical Risk Management
authorswithroles_txt_mv	Maselli DJ @@aut@@ Rogers L @@aut@@ Peters JI @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	481905820
id	DOAJ075226855
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ075226855</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309132941.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ075226855</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Maselli DJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash; National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MEDI-563</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">benralizumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-IL-5</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-5 blockage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-5 receptor blockade</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rogers L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peters JI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Therapeutics and Clinical Risk Management</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2018), Seite 2059-2068</subfield><subfield code="w">(DE-627)481905820</subfield><subfield code="w">(DE-600)2180573-8</subfield><subfield code="x">1178203X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2018</subfield><subfield code="g">pages:2059-2068</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-203X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2018</subfield><subfield code="h">2059-2068</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Maselli DJ
spellingShingle	Maselli DJ misc RM1-950 misc MEDI-563 misc benralizumab misc anti-IL-5 misc IL-5 blockage misc IL-5 receptor blockade misc Therapeutics. Pharmacology Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
authorStr	Maselli DJ
ppnlink_with_tag_str_mv	@@773@@(DE-627)481905820
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	1178203X
topic_title	RM1-950 Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use MEDI-563 benralizumab anti-IL-5 IL-5 blockage IL-5 receptor blockade
topic	misc RM1-950 misc MEDI-563 misc benralizumab misc anti-IL-5 misc IL-5 blockage misc IL-5 receptor blockade misc Therapeutics. Pharmacology
topic_unstemmed	misc RM1-950 misc MEDI-563 misc benralizumab misc anti-IL-5 misc IL-5 blockage misc IL-5 receptor blockade misc Therapeutics. Pharmacology
topic_browse	misc RM1-950 misc MEDI-563 misc benralizumab misc anti-IL-5 misc IL-5 blockage misc IL-5 receptor blockade misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Therapeutics and Clinical Risk Management
hierarchy_parent_id	481905820
hierarchy_top_title	Therapeutics and Clinical Risk Management
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)481905820 (DE-600)2180573-8
title	Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
ctrlnum	(DE-627)DOAJ075226855 (DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b
title_full	Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
author_sort	Maselli DJ
journal	Therapeutics and Clinical Risk Management
journalStr	Therapeutics and Clinical Risk Management
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
container_start_page	2059
author_browse	Maselli DJ Rogers L Peters JI
class	RM1-950
format_se	Elektronische Aufsätze
author-letter	Maselli DJ
author2-role	verfasserin
title_sort	benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
callnumber	RM1-950
title_auth	Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
abstract	Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody
abstractGer	Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody
abstract_unstemmed	Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai – National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
url	https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM https://doaj.org/toc/1178-203X
remote_bool	true
author2	Rogers L Peters JI
author2Str	Rogers L Peters JI
ppnlink	481905820
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RM1-950
up_date	2024-07-03T13:43:12.501Z
_version_	1803565601925365760
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ075226855</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309132941.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ075226855</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaee5e39e0ccd4b17845940b14ab2874b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Maselli DJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diego Jose Maselli,1 Linda Rogers,2 Jay I Peters1 1Division of Pulmonary Diseases and Critical Care, University of Texas Health, San Antonio, TX, USA; 2Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Mount Sinai &ndash; National Jewish Health Respiratory Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract: There are now multiple monoclonal antibodies targeting different inflammatory pathways of severe asthma. Benralizumab is a recently approved monoclonal antibody indicated for the treatment of severe eosinophilic asthma by targeting a subunit of the IL-5 receptor. Treatment with benralizumab results in significant reductions of blood and tissue eosinophils. Early studies report that this therapy has an adequate safety profile, and this was confirmed in later trials. Phase III studies have shown that benralizumab is effective in reducing the rate of exacerbations and improving asthma symptoms and quality of life in patients with severe eosinophilic asthma. Additionally, treatment with benralizumab has resulted in important reductions in the use of chronic oral corticosteroids. In this review, we evaluate the evidence up to date on the efficacy of benralizumab in severe eosinophilic asthma and explore the implications of this therapy in the ever-growing landscape of therapies for severe asthma. Keywords: MEDI-563, benralizumab, anti-IL-5, IL-5 antibody, IL-5 receptor antibody</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MEDI-563</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">benralizumab</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-IL-5</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-5 blockage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-5 receptor blockade</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rogers L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Peters JI</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Therapeutics and Clinical Risk Management</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2018), Seite 2059-2068</subfield><subfield code="w">(DE-627)481905820</subfield><subfield code="w">(DE-600)2180573-8</subfield><subfield code="x">1178203X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2018</subfield><subfield code="g">pages:2059-2068</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/aee5e39e0ccd4b17845940b14ab2874b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/benralizumab-an-add-on-treatment-for-severe-eosinophilic-asthma-evalua-peer-reviewed-article-TCRM</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-203X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2018</subfield><subfield code="h">2059-2068</subfield></datafield></record></collection>
score	7.398573

Nicht das Richtige dabei?

Schreiben Sie uns!

Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?